Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA4 | P22748 | 3/20 | 0.44 |
| ▸ | CA6 | P23280 | 3/20 | 0.44 |
| ▸ | CA5A | P35218 | 3/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | F13A1 | P00488 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9971087 | 1.00 | CYP2C19 (0.56) | CYP2C19CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL6960076 | 0.97 | EPHX1 (0.58) | CYP2C19CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL8850809 | 0.97 | EPHX1 (0.58) | CYP2C19CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL9260153 | 0.97 | EPHX1 (0.58) | CYP2C19CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL3024820 | 0.96 | CYP2C19 (0.53) | CYP2C19CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL5932994 | 0.96 | EPHX1 (0.56) | CYP2C19CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL26367204 | 0.96 | CYP2C19 (0.53) | CYP2C19CYP1A2EPHX1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8851500 | 0.94 | EPHX1 (0.55) | CYP2C19CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL15900056 | 0.93 | EPHX1 (0.61) | CYP2C19CYP1A2EPHX1MEN1KMT2A | |
| SCHEMBL7521377 | 0.93 | EPHX1 (0.61) | CYP2C19CYP1A2EPHX1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092356-A1 | UREMIC METABOLITE-ZWITTERIONIC HEMOCOMPATIBLE DIALYSIS MEMBRANES | UNIVERSITY OF SASKATCHEWAN (CA) | 2024-05-10 | — | — | WO | disclosed |
| WO-2023130021-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED DELIVERY PROPERTIES | PHIO PHARMACEUTICALS CORP. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-11459323-B2 | Monocyclic β-lactam compound for treating bacterial infection | MEDSHINE DISCOVERY INC. (CN) | 2022-10-04 | — | — | US | disclosed |
| EP-3578183-B1 | RNA INTERFERENCE IN OCULAR INDICATIONS | PHIO PHARM CORP (US) | 2021-09-08 | — | — | EP | disclosed |
| WO-2021138537-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED SYSTEMIC DELIVERY | PHIO PHARMACEUTICALS CORP. (US) | 2021-07-08 | — | — | WO | disclosed |
| US-20210115035-A1 | MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION | Shenzhen Optimum Biological Technology Co., Ltd (CN) | 2021-04-22 | — | — | US | disclosed |
| EP-3077050-B1 | METHODS FOR TREATMENT OF WOUND HEALING UTILIZING CHEMICALLY MODIFIED OLIGONUCLEOTIDES | PHIO PHARM CORP (US) | 2020-10-21 | — | — | EP | disclosed |
| US-9795687-B2 | Modularly assembled small molecules for the treatment of myotonic dystrophy type 1 | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170067056-A1 | RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170051288-A1 | METHODS FOR TREATING CANCER USING NUCLEIC ACIDS TARGETING MDM2 OR MYCN | RXI PHARMACEUTICALS CORPORATION (US) | 2017-02-23 | — | — | US | disclosed |
| US-9340786-B2 | RNA interference in dermal and fibrotic indications | RXI PHARMACEUTICALS CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160130578-A1 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | PHIO PHARMACEUTICALS CORP. | 2016-05-12 | — | — | US | disclosed |
| US-20160115482-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | PHIO PHARMACEUTICALS CORP. | 2016-04-28 | — | — | US | disclosed |
| US-9095504-B2 | RNA interference in ocular indications | RXI PHARMACEUTICALS CORPORATION | 2015-08-04 | — | — | US | disclosed |
| US-9080171-B2 | Reduced size self-delivering RNAi compounds | RXi Parmaceuticals Corporation (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140113950-A1 | INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS | RXI PHARMACEUTICALS CORPORATION (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130131142-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | PHIO PHARMACEUTICALS CORP. | 2013-05-23 | — | — | US | disclosed |
| US-20130131141-A1 | REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS | PHIO PHARMACEUTICALS CORP. | 2013-05-23 | — | — | US | disclosed |
| US-20020045780-A1 | Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment | BERGERON RAYMOND J (US) | 2002-04-18 | — | — | US | disclosed |
| US-6235794-B1 | ANTICANCER AGENT | UNIVERSITY OF FLORIDA | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045780-A1 | Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment | SRM, SLC7A1, CATSPER1 | CYP2C19 1807/4885CYP1A2 3146/4885EPHX1 3091/4885 |
| US-20130131142-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | RXRA, RXRB, RXRG | CYP2C19 4442/4885CYP1A2 4032/4885EPHX1 4038/4885 |
| US-11459323-B2 | Monocyclic β-lactam compound for treating bacterial infection | PEPD, COASY, MRPL21 | CYP2C19 49/4885CYP1A2 360/4885EPHX1 3099/4885 |
| US-20210115035-A1 | MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION | COASY, BCAT2, PEPD | CYP2C19 31/4885CYP1A2 256/4885EPHX1 3166/4885 |
| US-20160115482-A1 | RNA INTERFERENCE IN OCULAR INDICATIONS | RXRA, RXRB, RXRG | CYP2C19 4442/4885CYP1A2 4032/4885EPHX1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.